Cost-effectiveness of self-monitoring of blood glucose in patients with type 2 diabetes mellitus managed without insulin

CMAJ. Canadian Medical Association Journal

Volumn 182, Issue 1, 2010, Pages 28-34

  Cameron, Chris ^a   Coyle, Doug ^b   Ur, Ehud ^c,e   Klarenbach, Scott ^d,e  

^a CANADIAN AGENCY FOR DRUGS AND TECHNOLOGIES IN HEALTH   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

^e Canadian Optimal Medication Prescribing and Utilization Service Expert Review Committee   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; ANTIDIABETIC AGENT;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; HEALTH CARE UTILIZATION; HUMAN; INCIDENCE; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY OF LIFE; SELF MONITORING; SENSITIVITY ANALYSIS; TEST STRIP; BLOOD; DIABETES MELLITUS; ECONOMICS; PROSPECTIVE STUDY; UNITED KINGDOM;

ADULT; BLOOD GLUCOSE SELF-MONITORING; COST-BENEFIT ANALYSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; GREAT BRITAIN; HUMANS; HYPOGLYCEMIC AGENTS; PROSPECTIVE STUDIES;

EID: 77949404802     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.090765     Document Type: Article

References (49)

1. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008;32(Suppl 1):i-S201. Available: www.diabetes.ca/files/cpg2008/cpg-2008.pdf (accessed 2009 Oct 7).
2. Bodmer M, Meier C, Krahenbuhl S, et al. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabetes Care 2008;31:2086-91.
3. Canadian Agency for Drugs and Technologies in Health. Optimal therapy report: current utilization of blood glucose test strips in Canada. Ottawa (ON): The Agency; 2009. Available: www.cadth.ca/media/pdf/compus-CU-Report-BGTS.pdf (accessed 2009 Oct 7).
4. Cameron C, Virani A, Dean H, et al. Current utilization and expenditure on blood glucose test strips in Canada. Can J Diabetes. In press.
5. 2005/06 report card for the Ontario drug benefit program [PowerPoint presentation]. Toronto (ON): Ministry of Health and Long-Term Care; 2006. Available: www.health.gov.on.ca/englis/public/pub/ministry-reports/odb- report05/drug-rep.html (accessed 2009 Oct 7).
6. Utilization of oral antiglycemics in Canada, [unpublished dataset]. Ottawa (ON): Brogan, Inc.; 2008.
7. 2004/05 report card for the Ontario drug benefit program. [PowerPoint presentation]. Toronto (ON): Ministry of Health and Long-Term Care; 2005. Available: www.health.gov.on.ca/english/public/pub/ministry-reports/odb- report04/drug-rep..html (accessed 2009 Oct 7).
8. Diabetes in Canada. Highlights from the National Diabetes Surveillance System 2004-2005. Ottawa (ON): Public Health Agency of Canada; 2008. Available: www.phac-aspc.gc.ca/publicat/2008/dicndss-dacsnsd-04-05/pdf/dicndss- 04-05-eng.pdf (accessed 2009 Oct 7).
9. Laupacis A. Economic evaluations in the Canadian common drug review. Pharmacoeconomics 2006;24:1157-62.
10. Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146:473-81.
11. Canadian Agency for Drugs and Technologies in Health. Systematic review of use of blood glucose test strips for the management of diabetes mellitus. Ottawa (ON): The Agency; 2008. Available: www.cadth.ca/media/pdf/BGTS-SR-Report- of-Clinical-Outcomes.pdf (accessed 2009 Oct 9).
12. Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004;47:1747-59.
13. Mount Hood 4 Modeling Group. Computer modeling of diabetes and its complications: a report on the fourth Mount Hood Challenge Meeting. Diabetes Care 2007:30:1638-46 Available http://care.diabetesjournal.org/cgi/reprint/ 30/6/1638 (accessed 2009 Oct 7).
14. Alberta diabetes atlas 2007. Edmonton (AB): Institute of Health Economics; 2007. Available: www.achord.ca/documents/AlbertaDiabetesAtlas2007- 002.pdf (accessed 2009 Oct 7).
15. Hux JE, Booth GL, Slaughter PM, et al., editors. Diabetes in Ontario: an ICES practice atlas. Toronto (ON): Institute for Clinical Evaluative Sciences; 2003. Available: www.ices.on.ca/webpage.cfm?site-id=1&org-id= 31&morg-id=0&gsec-id=0&item-id=1312 (accessed 2009 Oct 7).
16. Harris SB, Ekoe JM, Zdanowicz Y, et al. Glycemic control and morbidity in the Canadian primary care setting (results of the diabetes in Canada evaluation study). Diabetes Res Clin Pract 2005;70:90-7.
17. Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada. 3rd ed. Ottawa (ON): The Agency; 2006. Available: www.cadth.ca/media/pdf/186-EconomicGuidelines-e. pdf (accessed 2009 Oct 7).
18. Ontario drug benefit formulary/comparative drug index: electronic version. [database online]. Toronto (ON): Ministry of Health and Long-Term Care; 2008. Available: www.health.gov.on.ca/english/providres/program/drug/odbf- eformulary.html (accessed 2007 Feb. 13).
19. Ontario drug benefit: dispensing fees. Toronto (ON): Ministry of Health and Long-Term Care; 2007. Available: www.health.gov.on.ca/english/public/pub/ drugs/dispense.html (accessed 2008 June 23).
20. OneTouch blood glucose meters. Bumaby (BC): LifeScan Canada Ltd; 2007. Available: www.onetouch.ca/english/index.asp (accessed 2009 Oct 7).
21. O'Reilly D, Hopkins R, Blackhouse G, et al. Development of an Ontario Diabetes Economic Model (ODEM) and application to a multidisciplinary primary care diabetes management program. Hamilton (ON): Program for Assessment of Technology in Health (PATH); 2006. Available: www.path-hta.ca/diabetes.pdf (accessed 2009 Oct 7).
22. Sullivan PW, Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Making 2006;26:410-20.
23. Sullivan PW, Lawrence WF, Ghushchyan V. A national catalog of preference-based scores for chronic conditions in the United States. Med Care 2005;43:736-49.
24. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002;22:340-9.
25. Berger ML, Bingefors K, Hedblom EC, et al., editors. Health care cost, quality, and outcomes: ISPOR book of terms. Lawrenceville (NJ): International Society for Pharmacoeconomics and Outcomes Research; 2003.
26. Consumer price index (CPI), 2001 basket content monthly (1992=100). In: CANSIM table. Ottawa (ON): Statistics Canada; 2007.
27. Canadian Agency for Drugs and Technologies in Health. Cost-effectiveness of blood glucose test strips in the management of adult patients with diabetes [DRAFT]. Ottawa (ON): The Agency; 2009. Available: www.cadth.ca/media/pdf/compus-Draft-BGTS-Consolidated-Econ-Report.pdf (accessed 2009 Oct 7).
28. Dahlof C, Dimenas E, Olofsson B. Documentation of an instrument for assessment of subjective CNS-related symptoms during cardiovascular pharmacotherapy. Cardiovasc Drugs Ther 1989;3:919-27.
29. Davidson MB, Castellanos M, Kain D, et al. The effect of self monitoring of blood glucose concentrations on glycated hemoglobin levels in diabetic patients not taking insulin: a blinded, randomized trial. Am J Med 2005;118:422-5.
30. Farmer A, Wade A, Goyder E, et al. Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial. BMJ 2007;335:132.
31. Guerci B, Drouin P, Grangé V, et al. Self-monitoring of blood glucose significantly improves metabolic control in patients with type 2 diabetes mellitus: the AutoSurveillance Intervention Active (ASIA) study. Diabetes Metab 2003;29:587-94.
32. Muchmore DB, Springer J, Miller M. Self-monitoring of blood glucose in overweight type 2 diabetic patients. Acta Diabetol 1994;31:215-9.
33. O'Kane MJ, Bunting B, Copeland M, et al. Efficacy of self monitoring of blood glucose in patients with newly diagnosed type 2 diabetes (ESMON study): randomised controlled trial. BMJ 2008;336:1174-7.
34. Schwedes U, Siebolds M, Mettes G; SMBG Study Group. Meal-related structured self-monitoring of blood glucose: effect on diabetes control in non-insulin-treated type 2 diabetic patients. Diabetes Care 2002;25:1928-32. Available: http://care.diabetesjournals.org/cgi/reprint/25/11/ 1928 (accessed 2009 Oct 7).
35. Barnett AH, Krentz AJ, Strojek K, et al. The efficacy of self-monitoring of blood glucose in the management of patients with type 2 diabetes treated with a gliclazide modified release-based regimen. A multicentre, randomized, parallel-group, 6-month evaluation (DINAMIC 1 study). Diabetes Obes Metab 2008;10:1239-47.
36. Palmer AJ, Dinneen S, Gavin JR, et al. Cost-utility analysis in a UK setting of self-monitoring of blood glucose in patients with type 2 diabetes. Curr Med Res Opin 2006;22:861-72.
37. Karter AJ, Ackerson LM, Darbinian JA, et al. Self-monitoring of blood glucose levels and glycemic control: the Northern California Kaiser Permanente Diabetes Registry. Am J Med 2001;111:1-9.
38. Scherbaum WA, Ohmann C, Abholz HH, et al. Effect of the frequency of self-monitoring blood glucose in patients with type 2 diabetes treated with oral antidiabetic drugs-a multi-centre, randomized controlled trial. PLoS One 2008;3:e3087.
39. Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2003;27(Suppl 2):i-S140. Available: www.diabetes.ca/cpg2003/downloads/ cpgcomplete.pdf (accessed 2009 Oct 7).
40. Ostgren CJ, Merlo J, Rastam L, et al. Atrial fibrillation and its association with type 2 diabetes and hypertension in a Swedish community. Diabetes Obes Metab 2004;6:367-74.
41. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5.
42. Calculating the U.S. population-based EQ-5D index score. Rockville (MD): Agency for Healthcare Research and Quality; 2005. Available: www.ahrq.gov/rice/EQ5Dscore.htm (accessed 2009 Oct 7).
43. Bowker SL, Majumdar SR, Johnson JA. Systematic review of indicators and measurements used in controlled studies of quality improvement for type-2 diabetes. Can J Diabetes 2005;29:230-8. Available: www.diabetes.ca/files/ Johnson-Systematic-Review-pages%20230-238.pdf (accessed 2009 Oct 7).
44. Tunis SL, Minshall ME. Self-monitoring of blood glucose in type 2 diabetes: cost-effectiveness in the United States. Am J Manag Care 2008;14:131-40.
45. Simon J, Gray A, Clarke P, et al. Cost effectiveness of self monitoring of blood glucose in patients with non-insulin treated type 2 diabetes: economic evaluation of data from the DiGEM trial. BMJ 2008;336:1177-80..
46. Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20(Suppl l):S5-26.
47. Stevens RJ, Kothari V, Adler AI, et al.; United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Land) 2001;101:671-9.
48. Lassere MN, Johnson KR, Boers M, et al. Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. J Rheumatol 2007;34:607-15.
49. Rosen CJ. The rosiglitazone story-lessons from an FDA Advisory Committee meeting. N Engl J Med 2007;357:844-6.